更正：删除标题和第一条要点中关于股价走势的不准确表述；将第一条要点中的“晚期临床试验”更正为“后续研究”；同时更正公司名称
7月13日 - ** 制药公司ANI Pharmaceuticals（ANIP.O）表示，其植入物在针对慢性非感染性葡萄膜炎的后续研究中达到了两个主要目标。慢性非感染性葡萄膜炎是一种易复发的炎症性眼病，可能导致视力丧失
** 试验显示，患者在接受Iluvien治疗六个月后，视力（以视力表字母数量衡量）平均提高了3.6个字母
** ANI表示，该药物还显著减轻了视网膜水肿，达到了该研究的另一主要目标
** Iluvien可在眼内持续释放低剂量类固醇，作用时间最长可达三年
** 最常见的治疗相关副作用包括眼压升高(6%) 和白内障(5%)，29% 的患者报告了治疗相关副作用
** Co计划于今年晚些时候在医学会议上公布详细的研究结果
** 截至上一交易日收盘，该股年内累计上涨4%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.